Review

Blood Pressure Monitoring in Cardiovascular Disease

  • While the practice of taking blood pressure readings at the physician’s office continues to be valid, home blood pressure monitoring is being increasingly used to enhance diagnostic accuracy and ensure a more personalized follow-up of patients. In the case of white coat hypertension and resistant arterial hypertension, ambulatory blood pressure monitoring is indispensable. Recent studies attach great importance to nocturnal blood pressure patterns, with a reduction in these becoming a treatment goal, a strategy known as chronotherapy. Home blood pressure monitoring is useful for both diagnosis and follow-up of arterial hypertension. Its use, particularly if combined with other patient-support interventions, serves to improve blood pressure control. Telemonitoring is associated with a decrease in blood pressure values and an increase in patient satisfaction. All studies highlight the importance of patients being supported by a multidisciplinary health care team, since blood pressure telemonitoring with a support team is more effective than simple data telemonitoring. Further studies are called for, especially on the illiterate population, with difficulties posed by technological accessibility and transcriptions into different languages. More cost-effectiveness studies and long-term results are needed to ascertain the true benefit of blood pressure telemonitoring.

    Citation: Carlos Menéndez Villalva, Xose Luis Muiño López-Alvarez, Martín Menéndez Rodríguez, María José Modroño Freire, Olalla Quintairos Veloso, Lea Conde Guede, Sandra Vilchez Dosantos, Manuel Blanco Ramos. Blood Pressure Monitoring in Cardiovascular Disease[J]. AIMS Medical Science, 2017, 4(2): 164-191. doi: 10.3934/medsci.2017.2.164

    Related Papers:

    [1] Jin Hwan Do . Genome-wide transcriptional comparison of MPP+ treated human neuroblastoma cells with the state space model. AIMS Molecular Science, 2015, 2(4): 440-460. doi: 10.3934/molsci.2015.4.440
    [2] Davide Lovisolo, Marianna Dionisi, Federico A. Ruffinatti, Carla Distasi . Nanoparticles and potential neurotoxicity: focus on molecular mechanisms. AIMS Molecular Science, 2018, 5(1): 1-13. doi: 10.3934/molsci.2018.1.1
    [3] Jade Sternberg, Miriam Wankell, V. Nathan Subramaniam, Lionel W. Hebbard . The functional roles of T-cadherin in mammalian biology. AIMS Molecular Science, 2017, 4(1): 62-81. doi: 10.3934/molsci.2017.1.62
    [4] Carlos Gutierrez-Merino, Dorinda Marques-da-Silva, Sofia Fortalezas, Alejandro K. Samhan-Arias . The critical role of lipid rafts nanodomains in the cross-talk between calcium and reactive oxygen and nitrogen species in cerebellar granule neurons apoptosis by extracellular potassium deprivation. AIMS Molecular Science, 2016, 3(1): 12-29. doi: 10.3934/molsci.2016.1.12
    [5] Navid J. Ayon . Features, roles and chiral analyses of proteinogenic amino acids. AIMS Molecular Science, 2020, 7(3): 229-268. doi: 10.3934/molsci.2020011
    [6] Jin Hwan Do . Apomorphine-induced pathway perturbation in MPP+-treated SH-SY5Y cells. AIMS Molecular Science, 2017, 4(3): 271-287. doi: 10.3934/molsci.2017.3.271
    [7] Abdulrahman Mahmoud Dogara, Ateeq Ahmed Al-Zahrani, Sarwan W. Bradosty, Saber W. Hamad, Aisha Abdullahi Mahmud, Hussain D. Almalki, Mustapha Abdullahi, Abubakar Abdullahi Lema, Hasan Nudin Nur Fatihah . In-vitro biological activity and in-silico studies of some volatile phytochemicals from the ethanol extract of Eugenia uniflora. AIMS Molecular Science, 2024, 11(3): 303-321. doi: 10.3934/molsci.2024018
    [8] Fatima Al-Hashimi, Salvador J. Diaz-Cano . Multi-target analysis of neoplasms for the evaluation of tumor progression: stochastic approach of biologic processes. AIMS Molecular Science, 2018, 5(1): 14-62. doi: 10.3934/molsci.2018.1.14
    [9] Marco Feligioni, Serena Marcelli, Erin Knock, Urooba Nadeem, Ottavio Arancio, Paul E. Fraser . SUMO modulation of protein aggregation and degradation. AIMS Molecular Science, 2015, 2(4): 382-410. doi: 10.3934/molsci.2015.4.382
    [10] Jian Zou, Fulton T. Crews . Glutamate/NMDA excitotoxicity and HMGB1/TLR4 neuroimmune toxicity converge as components of neurodegeneration. AIMS Molecular Science, 2015, 2(2): 77-100. doi: 10.3934/molsci.2015.2.77
  • While the practice of taking blood pressure readings at the physician’s office continues to be valid, home blood pressure monitoring is being increasingly used to enhance diagnostic accuracy and ensure a more personalized follow-up of patients. In the case of white coat hypertension and resistant arterial hypertension, ambulatory blood pressure monitoring is indispensable. Recent studies attach great importance to nocturnal blood pressure patterns, with a reduction in these becoming a treatment goal, a strategy known as chronotherapy. Home blood pressure monitoring is useful for both diagnosis and follow-up of arterial hypertension. Its use, particularly if combined with other patient-support interventions, serves to improve blood pressure control. Telemonitoring is associated with a decrease in blood pressure values and an increase in patient satisfaction. All studies highlight the importance of patients being supported by a multidisciplinary health care team, since blood pressure telemonitoring with a support team is more effective than simple data telemonitoring. Further studies are called for, especially on the illiterate population, with difficulties posed by technological accessibility and transcriptions into different languages. More cost-effectiveness studies and long-term results are needed to ascertain the true benefit of blood pressure telemonitoring.


    In recent years, fluorescent visual detection of metal ions has been regularly used due to highly sensitive, selective, cost-effective and operational simplicity [1,2,3,4,5]. Conventional approaches such as electrochemical sensors inductively coupled plasma mass, and atomic absorption-emission spectrometry are considered laborious, time-consuming and complex procedures [6,7]. Despite their high selectivity and sensitivity to detect the total amount of the metal analytes [8], still, these do not fit in the list of real-time detection and evaluation methods [9]. Therefore, simple, low-cost, and convenient approaches are needed for real-time recognition of metal ions. Recently reported probes and various types of biosensors are important owing to their highly selective and sensitive detection of toxic heavy metal ions and other environmentally-related contaminants [3,4,5,10,11,12]. Thus, many of such bio-sensing tools are widely used for medical and environmental monitoring applications [12,13,14,15,16].

    Excessive use of heavy metals for industrial applications has become a serious environmental concern for the last two decades [17,18]. Mercury is a highly toxic metal and is found in the atmosphere, land, and water [19]. Methyl-mercury, a derivative of mercury produced by microbial interaction, is even more lethal and can damage the intestine, lungs, kidney, heart nervous system and DNA causing Minamata and brain diseases following entrance into the body [14,20,21]. Based on its toxicity, international organizations such as the Environmental Protection Agency (EPA) and World health organization (WHO) have devised permissible mercury values for drinking water [22]. Hence, the development of sensitive and selective methods is highly essential for consistent monitoring and effective control of mercury-based environmental pollution.

    Mercury fluorescent chemo-sensors consist of various active moieties known as fluorophores such as xanthenes (rhodamines and fluorescein), dansyl, pyrene and 1, 8-naphthalamide [9,23,24,25,26]. Rhodamine-based fluorescent chemosensors have greater photostable properties of molar extinction-coefficient (ɛ), long emission and absorption wavelengths, excellent spirolactam configuration, enhanced quantum yield (Φ) and visual detection through turn-on fluorescence [27,28]. Rhodamine-based fluorescent chemosensors, both in open cycle (fluorescent) and spirocyclic ring (colorless) form, have been developed for the recognition of heavy metals [29,30]. Reports have shown that oxygen and nitrogen at the binding location have an excellent affinity for mercury metal ions [4,5,31].

    The present study aimed to develop a mercury metal ion rhodamine-based fluorescent chemosensor with enhanced sensitivity and selectivity assuming that the prepared sensor could be cost-effective and simple operative for real-time in-field investigation purposes. Scheme 1 illustrates a synthetic route of the desired chemical sensor (S) synthesized from rhodamine as a fluorophore. The characteristic structure of the newly developed chemosensor was confirmed by 1H NMR and mass spectroscopy. The colorless, nonfluorescent, rhodamine-based chemosensor when interacting with mercury metal ions changes to highly fluorescent pink color through spirolactam ring opening by chemical coordination interactions [32]. This characteristic property could be used for sensitive and selective monitoring of mercury metal ions as a mobile probe and color matching kit by observing molar extinction coefficient values against the concentration of mercury ions in the test sample.

    Figure Scheme 1.  A synthetic pathway for chemosensor development.

    All the chemical or reagents were mainly purchased from Sigma-Aldrich USA, Adamas-Beta, and Shanghai Chemical Reagent Co. Ltd., China, and used as received. The solutions for different metal cations were prepared from their nitrates, chloride and perchlorate salts. PerkinElmer LS 55 and UV-Schimadzu 2600 spectrophotometer were used for fluorescence and UV-Vis measurements, respectively. For 1H, 13C and Mass analysis, mercury plus 400 spectrometer (Varian, USA) and Instrument: Waters ACQUITY UPLC & Micromass Q-TOF Premier Mass Spectrometer was used.

    A rhodamine-based fluorescent sensor was developed using rhodamine B acid chloride (RB-Cl) by adopting an earlier described process with slight modifications [33]. Briefly, 2.0 g of 4.2 mM phosphorous oxychloride in dichloroethane (DCE) was dropwise added to rhodamine B solution under continuous stirring and finally refluxing the solution for four h. The resultant reaction mixture was then cooled down to room temperature, and the solvent was eliminated under reduced pressure to obtain a purple sticky solid (RB-Cl). The collected RB-CI was thawed in 20 mL of anhydrous CH3CN at room temperature. Following that, up to 20 mL mixture comprised on five mL of anhydrous trimethylamine and 1.4 g (8.4 mM) 2-aminothiazole in acetonitrile was added dropwise using an ice bath. After cooling down to room temperature; the mixture was poured into 100 mL of distilled water, extracted with DCM and dried over anhydrous Na2SO4. The organic layer was evaporated, and the crude product was separated by column chromatography using 9:1 (v/v) DCM/CH3OH as an eluent. The formation of S was confirmed by 1H NMR and mass spectrometry (Figure 1).

    Figure 1.  (a) 1H NMR spectra in CDCl3 and (b) MS spectra of S.

    Initially, all the stock solutions were prepared using deionized water at a concentration of 100 mM. For mercury detection, up to 10 mL of acetonitrile was used to prepare the stock solution of sensor S with a final concentration of 100 mM. All freshly prepared stock solutions were further diluted to the desired concentration by adding the required amount of water. The spectral investigations were carried out in MeCN/H2O (8:2 v/v) mixed solution. The samples were excited at a wavelength of λmax = 550 nm, accompanied by excitation and emission slit width of = 15.0 nm. Similarly, the UV-Visible experiments were carried out within a wavelength of 400–700 nm in a quartz cuvette.

    The fluorescence and UV-Vis responses of S towards different metal cations were measured in CH3OH: H2O (8:2 v/v) at 583 and 559 nm, using 10 µM of S. The emission and absorbance intensities were fitted to Benesi-Hildebrand equations (1 and 2).

    1Δ(AA0)=1Ka(AmaxA0)[Cu2+]+1(AmaxA0) (1)
    1Δ(FF0)=1Ka(FmaxF0)[Hg2+]+1(FmaxF0) (2)

    Where A/F and A0/F0 is absorbance/emission intensity of the S solution in the existence of Hg2+; Amax/Fmax is the saturated absorbance/emission in case of much more presence of Hg2+; concentration of the mercury ion is presented as [Hg2+]. Binding constants was "Ka" calculated from UV-visible records for Hg2+.

    The geometries of S and S-Hg2+ were determined by using density functional theory (DFT) calculations with the hybrid-generalized gradient approximation (HGGA) functional B3LYP. The effective core potential LanL2DZ basis and binary valence 3–21g basis set were allocated to (C, N, H, O, and Br) and metallic elements respectively, which have been proved an effective method for investigating the luminous mechanism of fluorescence probe. The Gaussian09 program package was for these calculations [34,35].

    The practical applicability of the chemical sensor S was determined by measuring Hg2+ in wastewater samples. The contaminated wastewater samples were collected from the industrial area of Shanghai, China. Prior to measurements, following pH adjustment to neutral using phosphate buffer, the neutralized wastewater samples with a 20 mL working volume were passed through the microfiltration membranes. Different aliquots of the test samples were spiked with different concentrations, i.e., 0.1, 0.2, 0.4, 0.6, 0.8, 1.0 µM of freshly prepared mercury solution. The resulting samples were further treated with sensor S to give the final mixture (2.0 mL) containing S with final concentration of 10 mM and mercury (0.1, 0.2, 0.4, 0.6, 0.8, 1.0 µM) for 10 min at room temperature, and the absorbance was measured. The results were reported as the mean ± standard deviation of triplicate experiments for mercury and shown in Table 1.

    Table 1.  Determination of Hg2+ ions in industrial wastewater.
    Sample Hg2+ spiked (µM) Hg2+ recovered (µM) Recovery (%)
    Industrial wastewater 0.0 Not detected Not detected
    0.2 0.221 ± 0.010 110.5
    0.4 0.398 ± 0.014 99.5
    0.6 0.625 ± 0.036 104.1
    0.8 0.824 ± 0.006 103
    1.0 0.996 ± 0.017 99.6

     | Show Table
    DownLoad: CSV

    The spectral investigations (UV-Vis and fluorescence) of the newly fabricated chemical sensor S were carried out by titration experiments in acetonitrile: water system (8:2 v/v). The blank solution of S (10 µM) shows no significant enhancement of fluorescence as well as absorption intensities at 583 nm and 558 nm, respectively.

    This turn-off response shows that the chemical sensor S exists in its ring-closed form. However, upon the introduction of Hg2+, a new emission peak at 583 nm appeared, the intensity of the emission band goes on increasing as the concentration of Hg2+ was increased from 0 to 40 µM. Also, the color of the solution changes from colorless to pink. This colorimetric change accompanied by the increased intensity value reveals that the sensor S exists in its ring-open form. This colorimetric change proves that the sensor S can serve as a bare-eye detector for Hg2+. Similarly, the sensitive nature of the S was investigated by treating 10 µM solution of perchlorates, chlorides and nitrate solutions of different metal cations such as, Ag+, Al3+, Ba2+, Ca2+, Cd2+, Fe3+, Fe2+, K+, Li+, Mg2+, Mn2+, Cu2+, Pb2+, Ni+, Na+ and Zn2+. In CH3OH: H2O (8:2 v/v). Among all the competitive metal cations, only Hg2+ causes a significant change in the spectral pattern of S (Figure 2a, 2b). The binding affinity of the chemical sensor S was evaluated by using the emission titration data (Figure 3a). As shown in Figure 3b, the emission intensity increases to a certain value when the concentration of S and Hg2+ is equal to 1 equivalent. After that, the increase in intensity attains equilibrium.

    Figure 2.  Selective response of S (10 μM) towards different metal cations (10 μM) (a) fluorescence at 583 nm and (b) absorption at 558 nm, respectively.
    Figure 3.  Titration data (emission and absorbance a and d) of S (10 μM) in response to the varying concentration of Hg2+ (0–40 μM) (b, e) Emission and absorption intensity (d, f) Job's plot to calculate binding stoichiometry.

    Further, the binding stoichiometry was calculated by the method of continuous variables. During the process, the overall concentration of S and analyte remains constant (10 μM). After plotting the mole fraction of concentrations of S and analyte against corresponding intensity values, it was found that the binding stoichiometry of the complex S-Hg2+ was equal to 1:1 (Figure 3c). Finally, the equation 1 and 2 given in material method section was used to calculate the binding constant of the complex S-Hg2+. The calculated value was equal to 4.72 × 10 4 M−1. Similarly, the UV-Vis titration experiments were also carried out. The binding stoichiometry and binding constant calculated from UV-Vis titration data were in good agreement with the results obtained from emission titration experiments (Figure 3df).

    The lower limit of detection (LOD) was calculated with the slope of linear fit obtained from the emission and absorption intensity data (Figure 4a and 4b). Equation 3 was used to calculate the LOD by fitting the linear fit data (inset Figure 5a and 5b) into the equation. The calculated value was as low as 6.9 μM.

    LOD=3SD/Slope (3)
    Figure 4.  Linear fit obtained from the (a) emission and (b) absorption intensity data to calculate LOD.
    Figure 5.  Frontier molecular orbitals and electron density distributions of (a) S (b) S-Hg2+.

    Computational study of the probe S and S-metal ion complex was carried out to gain an insight into the coordination of Hg2+ with a chemical sensor and the resulting colorimetric changes. The density functional theory (DFT) method along with the hybrid-generalized gradient approximation (HGGA) functional B3LYP was used to optimize the ground-state structures of sensor S and S-based complexes. A Gaussian09 program package was employed to record all the calculations. The orbital energies and spatial distributions of HOMO and LUMO of S and S-Hg2+ were also calculated and it can be seen in Figure 5a and 5b that the π electronic cloud of HOMO of S-Hg2+ is located on the imide carbonyl group of rhodamine moiety, while most of the LUMO orbitals are positioned at center of the analyte (Hg2+). Furthermore, as compared to the S, the energy gap between the HOMO-LUMO of S-Hg2+ becomes smaller.

    Meanwhile, the HOMO−LUMO energy gap of the complex becomes much smaller relative to that of probe S. The energy gaps between HOMO and LUMO in the probe S and S-Hg2+ complex were 85.15 and 9.79 kcal/mol, respectively. This low energy values indicate that the Hg2+ binds well with S through bi-coordination, and the complete complex presents a planar geometry. Further, we can conclude that these low energy complexes formed by the coordination of the oxygen atom of the carbonyl group of imide linkage and the Sulphur atom of the thiazole moiety. On the bases of these calculations, the proposed binding mechanism is shown in scheme 2.

    Figure Scheme 2.  Proposed binding mode of the analyte with a chemical sensor.

    As it is evident from the spectral investigations (emission and absorption) that the probe S selectively binds with Hg2+ resulting in the formation of complex S-Hg2+. Another important feature of the sensor S is its reversibility and sensitivity. We have tried to explain the influence of different anions on metal-ligand complexation (turn-on) state and to generate the turn-off state of the probe S. It can be seen from the Figure 6a and 6b that adding disodium EDTA (10 μM) to the solution of S-Hg2+ regenerates the original spectra as in case of S. While the other anions such as F, Br, NO3, I, SO42−, CH3COO (10 μM each) etc. have no effect on the spectra obtained from S-Hg2+. Hence, we can conclude that the addition of EDTA2− can only generate a reversible change (fluorescent to non-fluorescent) to the solution of S-Hg2+. This reversible change reveals that the complex formation is reversible in the presence of disodium EDTA. Similarly, the interference study of the competitive cations was also investigated by using the equimolar solution of different metal cations to the solution of S-Hg2+. It is evident from the Figure 7a and 7b that all the interfering cations do not affect the emission and absorption intensities of the complex. Therefore, it can be concluded that the sensor S is highly sensitive and selective for Hg2+ only.

    Figure 6.  Regeneration of original spectra by the interaction of EDTA2-.
    Figure 7.  Competitive cations study of S by using equimolar concentration of competitive cations to the solution of S-Hg2+.

    Considering the Hg2+ as a toxic metal ion, the sensor S was employed to detect Hg2+ in the environmental wastewater collected from the river near the industrial area of Shanghai city. Then the as-prepared aliquot of this wastewater was analyzed with S followed by spiking with Hg2+ at different concentrations as discussed in the materials and methods section. The fluorescence intensity was measured at 583 nm and related linearly with the concentration of the analyte. For control, the same experiment was carried out with distilled water (Figure 8a and 8b). The results obtained are summarized in Table 1.

    Figure 8.  Linear plot of changes of fluorescence intensity of S at 583 nm versus spiked concentrations of mercury ions from 0 to 1.0 µM (a) industrial wastewater (b) distilled water.

    The current study demonstrated a new type of rhodamine-assisted chemosensor for the monitoring and detection of highly toxic environmental pollutant Hg2+ in aqueous systems. Results evidenced that the chemical sensor displays a real-time fluorometric response with high selectivity and sensitivity to distinguish Hg2+ in the partial aqueous media. Both, the binding affinity and detection limit were calculated to be 4.72 × 10 4 M−1 and 6.9 µM, respectively. Further, the complex between the chemical sensor and Hg2+ was observed to be reversible in the presence of EDTA2−. Taken together, all these properties suggest that the chemo-sensor might display great potential in the field of environmental monitoring of toxic elements.

    This work was financially supported by Young academic leaders in Jiangsu Province, Six talent peaks project in Jiangsu Province (2015-SWYY-026), and A study on highly-efficient biotransformation of oleic acid and linoleic acid to γ-decalactone in Yarrowia lipolytica based on synthetic biology (21606097). All authors are grateful to their representative institutes/universities for providing research facilities.

    All authors declare no conflict of interest in any capacity.

    [1] Bonafini S, Fava C (2015) Home blood pressure measurements: Advantages and disadvantages compared to office and ambulatory monitoring. Blood Press 24: 325–332. doi: 10.3109/08037051.2015.1070599
    [2] Wolak T, Wilk L, Paran E, et al. (2013) Is it possible to shorten ambulatory blood pressure monitoring? J Clin Hypertens (Greenwich) 15: 570–574. doi: 10.1111/jch.12123
    [3] O'Brien E, Parati G, Stergiou G, et al. (2013) European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 31: 1731–1768. doi: 10.1097/HJH.0b013e328363e964
    [4] Norma M Kaplan, George Tomas, Marc Pohl, et al. (2016) Blood pressure measurement in the diagnosis and management of hypertension in adults.
    [5] Krause T, Lovibond K, Caulfield M, et al. (2011) Management of hypertension: summary of NICE guidance. BMJ (Clinical Res) 343: 1–6.
    [6] Siu AL, U.S. Preventive Services Task Force (2015) Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 163: 778–786.
    [7] Chobanian AV, Bakris GL, Black HR, et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206–1252. doi: 10.1161/01.HYP.0000107251.49515.c2
    [8] Kaplan NM, Townsend RR (2015) Ambulatory and home blood pressure monitoring and white coat hypertension in adults.
    [9] Hermida RC, Ayala DE, Portaluppi F (2007) Circadian variation of blood pressure: The basis for the chronotherapy of hypertension. Advance Drug Delivery Rev 9: 904–922.
    [10] Andersen MJ, Khawandi W, Agarwal R (2005) Home blood pressure monitoring in CKD. Am J Kidney Dis 45: 994–1001. doi: 10.1053/j.ajkd.2005.02.015
    [11] Pickering TG, Miller NH, Ogedegbe G, et al. (2008) Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension 52: 10–29. doi: 10.1161/HYPERTENSIONAHA.107.189010
    [12] Parati G, Pickering TG (2009) Home blood-pressure monitoring: US and European consensus. Lancet 373: 876–878. doi: 10.1016/S0140-6736(09)60526-2
    [13] Niiranen TJ, Hänninen MR, Johansson J, et al. (2010) Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: The finn-home study. Hypertension 55: 1346–1351. doi: 10.1161/HYPERTENSIONAHA.109.149336
    [14] Verberk WJ, Kroon AA, Kessels AGH, et al. (2005) Home blood pressure measurement: A systematic review. J Am College Cardiology 46: 743–751. doi: 10.1016/j.jacc.2005.05.058
    [15] Myers MG (2010) A proposed algorithm for diagnosing hypertension using automated office blood pressure measurement. J Hypertension 28: 703–708. doi: 10.1097/HJH.0b013e328335d091
    [16] Powers BJ, Olsen MK, Smith VA, et al. (2011) Measuring blood pressure for decision making and quality reporting: Where and how many measures? Ann Intern Med 154: 781–788. doi: 10.7326/0003-4819-154-12-201106210-00005
    [17] Mesas A E, Leon-muñoz L, Rodriguez-artalejo F, et al. (2011) The effect of coffee on blood pressure and cardiovascular disease among hypertensive individuals: Meta-analysis. J Clinical Hypertension 13: A42. doi: 10.1111/j.1751-7176.2010.00379.x
    [18] Other U (2001) Blood pressure measurement. BMJ 322: 1043–1047. doi: 10.1136/bmj.322.7293.1043
    [19] Pickering TG, Hall JE, Appel LJ, et al.(2005) Recommendations for blood pressure measurement in humans: an AHA scientific statement from the Council on high blood pressure research professional and public education subcommittee.J Cinical Hypertens 7: 102–109.
    [20] Mancia G, Fagard R, Narkiewicz K, et al. (2013) ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 31: 1281–1357. doi: 10.1097/01.hjh.0000431740.32696.cc
    [21] Mancia G, De Backer G, Dominiczak A, et al. (2007) ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 25: 1751–1762. doi: 10.1097/HJH.0b013e3282f0580f
    [22] O'Brien (2005) Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 23: 697–701. doi: 10.1097/01.hjh.0000163132.84890.c4
    [23] U.S. Preventive Services Task Force (2007) Screening for high blood pressure: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 147(11):783–786.
    [24] Franklin SS, Thijs L, Hansen TW, et al. (2013) White-coat hypertension new insights from recent studies. Hypertension 62: 982–987. doi: 10.1161/HYPERTENSIONAHA.113.01275
    [25] NICE (2011) Hypertension in adults: diagnosis and management. NICE Guidel :1–38.
    [26] James PA, Oparil S, Carter BL, et al. (2013) Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Jama 1097: 1–14.
    [27] Coca A, Bertomeu V, Dalfó A, et al. (2007)Blood pressure self measurement: Spanish consensus document. Nefrol Publicación La Soc Española Nefrol 27: 139–153
    [28] Bangalore S, Qin J, Sloan S, et al. (2010) What is the optimal blood pressure in patients after acute coronary syndromes? Circulation 122: 2142–2151. doi: 10.1161/CIRCULATIONAHA.109.905687
    [29] Vokó Z, Bots ML, Hofman A, et al. (1999) shaped relation between blood pressure and stroke in treated hypertensives. Hypertension 34: 1181–1185. doi: 10.1161/01.HYP.34.6.1181
    [30] Pahor M, Shorr RI, Cushman WC, et al. (1999) The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 159: 2004–2009. doi: 10.1001/archinte.159.17.2004
    [31] Pickering TG (1988) The influence of daily activity on ambulatory blood pressure. Am Hear Jan 116: 1141–1146. doi: 10.1016/0002-8703(88)90178-0
    [32] Agarwal R, Andersen M (2006) Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int 69: 1175–1180. doi: 10.1038/sj.ki.5000247
    [33] Asayama K, Ohkubo T, Kikuya M, et al (2004) Prediction of stroke by self-measurement of blood pressure at home versus casual screening blood pressure measurement in relation to the Joint National Committee 7 classification: The Ohasama study. Stroke 35: 2356–2361. doi: 10.1161/01.STR.0000141679.42349.9f
    [34] Agarwal R, Bills JE, Hecht TJW, et al. (2011) Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control. Hypertension 57: 29–38. doi: 10.1161/HYPERTENSIONAHA.110.160911
    [35] Uhlig K, Patel K, Ip S, et al. (2013) Self-Measured Blood Pressure Monitoring in the Management of Hypertension. A systematic review and meta-analysis. Improve Patient Care 159.
    [36] Cappuccio FP, Kerry SM, Forbes L, et al. (2004) Blood pressure control by home monitoring: meta-analysis of randomised trials. Br Med J 329: 145. doi: 10.1136/bmj.38121.684410.AE
    [37] Powers BJ, Adams MB, Svetkey LP, et al. (2009) Two Self-management Interventions to Improve Hypertension Control. Ann Intern Med 151: 687–696. doi: 10.7326/0000605-200911170-00148
    [38] McManus RJ, Mant J, Haque MS, et al.(2014) Effect of Self-monitoring and Medication Self-titration on Systolic Blood Pressure in Hypertensive Patients at High Risk of Cardiovascular Disease. Jama 312: 799.
    [39] McManus RJ, Mant J, Bray EP, et al (2010) Telemonitoring and self-management in the control of hypertension (TASMINH2): A randomised controlled trial. Lancet 376: 163–172. doi: 10.1016/S0140-6736(10)60964-6
    [40] Yi SS, Tabaei BP, Angell SY, et al. (2015) Self-blood pressure monitoring in an urban, ethnically diverse population: a randomized clinical trial utilizing the electronic health record. Circulation 138–145.
    [41] Parati G, Stergiou GS, Asmar R, et al. (2010) European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens 24: 779–785. doi: 10.1038/jhh.2010.54
    [42] Dasgupta K, Quinn RR, Zarnke KB, et al.(2014) The 2014 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 30: 485–501.
    [43] Daskalopoulou SS, Rabi DM, Zarnke KB, et al. (2015) The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Can J Cardiol 31: 549–568. doi: 10.1016/j.cjca.2015.02.016
    [44] Avenue G (2011) Optimal Schedule for Home Blood Pressure Measurement. Hypertension 1081–1086.
    [45] Lauer RM, Clarke WR (1989) Childhood risk factors for high adult blood pressure: the Muscatine Study. Pediatrics 84: 633–641.
    [46] Sun SS, Grave GD, Siervogel RM, et al. (2007) Systolic blood pressure in childhood predicts hypertension and metabolic syndrome later in life. Pediatrics 119: 237–246. doi: 10.1542/peds.2006-2543
    [47] Blumenthal S, Epps R, Heavenrich R (1987) Report of the Second Task Force on Blood Pressure Control in Children. Pediatrics 79: 797–820.
    [48] The Fourth Report on the Diagnosis, Evaluation and T of HBP in C and A (2004) National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. Pediatrics 114: 555–576. doi: 10.1542/peds.114.2.S2.555
    [49] Rosner B, Prineas RJ, Loggie JMH, et al. (1993) Blood pressure nomograms for children and adolescents, by height, sex, and age, in the United States. J Pediatr 123(6): 871–886.
    [50] Joseph T Flynn (2017) Ambulatory blood pressure monitoring in children.
    [51] Williams CL, Daniels SR, Robinson TN, et al. (2002) Cardiovascular health in childhood. A statement for health professionals from the committee on atherosclerosis, hypertension, and obesity in the young of the council on cardiovascular disease in the young, Americam Heart Association. Circulation 106: 143–160.
    [52] Flynn JT (2011) Ambulatory blood pressure monitoring in children: imperfect yet essential. Pediatr Nephrol 26: 2089–2094. doi: 10.1007/s00467-011-1984-9
    [53] Sorof JM, Poffenbarger T, Franco K, et al. (2001) Evaluation of white coat hypertension in children: Importance of the definitions of normal ambulatory blood pressure and the severity of casual hypertension. Am J Hypertens 14: 855–860. doi: 10.1016/S0895-7061(01)02180-X
    [54] Lande MB, Meagher CC, Fisher SG, et al. (2008) Left ventricular mass index in children with white coat hypertension. J Pediatr153: 50–54.
    [55] Seeman T, Palyzová D, Dušek J, et al. (2017) Reduced nocturnal blood pressure dip and sustained nighttime hypertension are specific markers of secondary hypertension. J Pediatr 147: 366–371.
    [56] Flynn J, Daniels S, Hayman L, et al.(2014) Update: Ambulatory blood pressure monitoring in children and adolescents: A scientific statement from the American Heart Association. Hypertension 63: 1116–1135.
    [57] Urbina E, Alpert B, Flynn J, et al. (2008) Ambulatory Blood Pressure Monitoring in Children and Adolescents: Recommendations for Standard Assessment: A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the Council on Cardiovas. Hypertension 52: 433–451. doi: 10.1161/HYPERTENSIONAHA.108.190329
    [58] Aronow WS, Fleg JL, Pepine CJ, et al. (2011) Expert Consensus Document ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. J Am College Cardiology 57: 2037–2114. doi: 10.1016/j.jacc.2011.01.008
    [59] Ishikawa J, Ishikawa Y, Edmondson D, et al. (2011) Age and the difference between awake ambulatory blood pressure and office blood pressure: a meta-analysis. Blood Press Monit 16: 159–167. doi: 10.1097/MBP.0b013e328346d603
    [60] Stergiou GS, Ntineri A, Kollias A (2017) Changing relationship among office, ambulatory, and home blood pressure with increasing age: A neglected issue. Hypertension 64: 931–932.
    [61] US Preventive Services Task Force (2017) Final Recommendation Statement: High Blood Pressure in Adults.
    [62] Weber MA, Schiffrin EL, White WB, et al. (2014) Clinical Practice Guidelines for the Management of Hypertension in the Community. J Clin Hypertens 16: 14–26. doi: 10.1111/jch.12237
    [63] Bangalore S, Messerli FH, Wun CC, et al. (2010) J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 31: 2897–2908. doi: 10.1093/eurheartj/ehq328
    [64] Maselli M, Giantin V, Franchin A, et al. (2014) Detection of blood pressure increments in active elderly individuals: the role of ambulatory blood pressure monitoring. Nutr Metab Cardiovasc Dis 24: 914–920. doi: 10.1016/j.numecd.2014.01.003
    [65] Angeli F, Reboldi G, Verdecchia P (2010) Masked hypertension: Evaluation, prognosis, and treatment. Am J Hypertens 23: 941–948. doi: 10.1038/ajh.2010.112
    [66] Cacciolati C, Hanon O, Alpérovitch A, et al. (2011) Masked hypertension in the elderly: cross-sectional analysis of a population-based sample. Am J Hypertens 24: 674–680. doi: 10.1038/ajh.2011.23
    [67] Verberk WWJ, Omboni S, Kollias A, et al. (2016) Screening for atrial fibrillation with automated blood pressure measurement: Research evidence and practice recommendations. Int J Cardiol 203: 465–473. doi: 10.1016/j.ijcard.2015.10.182
    [68] Calhoun D A, Jones D, Textor S, et al. (2008) Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 117: 1403–1419.
    [69] De la Sierra A, Segura J, Banegas JR, et al.(2011) Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57: 898–902.
    [70] Jiménez Navarro MF (2016) Comentarios a la guía ESC 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica. Rev Española Cardiol 69: 894–899. doi: 10.1016/j.recesp.2016.08.009
    [71] Pickering TG (1988) Blood pressure monitoring outside the office for the evaluation of patients with resistant hypertension. Hypertension 11: II96-100.
    [72] Lazaridis AA, Sarafidis PA, Ruilope LM (2015) Ambulatory Blood Pressure Monitoring in the Diagnosis, Prognosis, and Management of Resistant Hypertension: Still a Matter of our Resistance? Curr Hypertens Rep 17.
    [73] Brown MA, Buddle ML, Martin A (2001) Is resistant hypertension really resistant? Am J Hypertens 14: 1263–1269. doi: 10.1016/S0895-7061(01)02193-8
    [74] Ríos M, Domínguez-Sardiña M, Ayala D, et al. (2013) Prevalence and clinical characteristics of isolated-office and true resistant hypertension determined by ambulatory blood pressure monitoring. Chronobiol Int 30.
    [75] Cardoso CRL, Salles GF (2016) Prognostic Importance of Ambulatory Blood Pressure Monitoring in Resistant Hypertension: Is It All that Matters? Curr Hypertens Rep 18: 85. doi: 10.1007/s11906-016-0693-y
    [76] Salles GF, Cardoso CL, Muxfeldt ES (2008) Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med 168: 2340–2346. doi: 10.1001/archinte.168.21.2340
    [77] Ayala DE, Hermida RC, Mojón A, et al. (2012) Cardiovascular Risk of Resistant Hypertension: Dependence on Treatment-Time Regimen of Blood Pressure–Lowering Medications. Chronobiol Int 528: 1–13.
    [78] Calhoun DA, Raymond MD, Townsens MD (2016) Treatment of resistant hypertension.
    [79] Doroszko A, Janus A, Szahidewicz-Krupska E, et al. (2016) Resistant hypertension. Adv Clin Exp Med 25: 173–183. doi: 10.17219/acem/58998
    [80] Muxfeldt E, Bloch K, Nogueira A, et al. (2003) Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Press Monit 8: 181–185.
    [81] Muxfeldt ES, Salles GF (2013) How to use ambulatory blood pressure monitoring in resistant hypertension. Hypertens Res 36: 385–389. doi: 10.1038/hr.2013.17
    [82] Williams B, Macdonald TM, Morant S, et al. (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (Pathway-2): A randomised, double-blind, crossover trial. Lancet 386: 2059–2068. doi: 10.1016/S0140-6736(15)00257-3
    [83] Dudenbostel T, Siddiqui M, Oparil S, et al. (2016) Refractory hypertension: A novel phenotype of antihypertensive treatment failure. Hypertension 67: 1085–1092. doi: 10.1161/HYPERTENSIONAHA.116.06587
    [84] Hermida RC, Smolensky MH, Ayala DE, et al. (2013) Recomendaciones 2013 para el uso de la monitorización ambulatoria de la presión arterial para el diagnóstico de hipertensión en adultos, valoración de riesgo cardiovascular y obtención de objetivos terapéuticos (resumen). Clínica e Investig en Arterioscler 25: 74–82. doi: 10.1016/j.arteri.2013.03.002
    [85] Sheikh S, Sinha A, Agarwal R (2011) Home Blood Pressure Monitoring: How Good a Predictor of Long-Term Risk? Curr Hypertens Rep 13: 192–199. doi: 10.1007/s11906-011-0193-z
    [86] Hermida RC, Moyá A, Ayala DE (2015) Monitorización ambulatoria de la presión arterial en diabetes para valoraci??n y control de riesgo vascular. Endocrinologiay Nutricion 62: 400–410.
    [87] Mancia G, Verdecchia P (2015) Clinical Value of Ambulatory Blood Pressure: Evidence and Limits. Circ Res 116: 1034–1045. doi: 10.1161/CIRCRESAHA.116.303755
    [88] Leitão CB, Canani LH, Silveiro SP, et al. (2007) Ambulatory blood pressure monitoring and type 2 diabetes mellitus. Arq Bras Cardiol 89: 315–321, 347–354
    [89] Care D (2016) Standards of Medical Care in Diabetes : Summary of Revisions. Diabetes Care 39: S4–5. doi: 10.2337/dc16-S003
    [90] Coca A, Camafort M, Doménech M, et al. (2013) Ambulatory blood pressure in stroke and cognitive dysfunction. Curr Hypertens Rep 15: 150–159. doi: 10.1007/s11906-013-0346-3
    [91] Castilla-Guerra L, Fernández-Moreno M del C, Espino-Montoro A, et al. (2009) Ambulatory blood pressure monitoring in stroke survivors: Do we really control our patients? Eur J Intern Med 20: 760–763. doi: 10.1016/j.ejim.2009.09.004
    [92] Castilla-Guerra L, Fernandez-Moreno (2016) Chronic Management of Hypertension after Stroke: The Role of Ambulatory Blood Pressure Monitoring. J stroke 18: 31–37. doi: 10.5853/jos.2015.01102
    [93] Agarwal R (2009) Home and ambulatory blood pressure monitoring in chronic kidney disease. Curr Opin Nephrol Hypertens 18: 507–512. doi: 10.1097/MNH.0b013e3283319b9d
    [94] Agarwal R, Peixoto AJ, Santos SFF, et al. (2009) Out-of-office blood pressure monitoring in chronic kidney disease. Blood Press Monit 14: 2–11. doi: 10.1097/MBP.0b013e3283262f58
    [95] Parati G, Ochoa JE, Bilo G, et al.(2016) Hypertension in chronic kidney disease part 1: Out-of-office blood pressure monitoring: Methods, thresholds, and patterns. Hypertension 67: 1093–1101.
    [96] Mehta R, Drawz PE (2011) Is nocturnal blood pressure reduction the secret to reducing the rate of progression of hypertensive chronic kidney disease? Curr Hypertens Rep 13: 378–385. doi: 10.1007/s11906-011-0217-8
    [97] Verdecchia P (2000) Prognostic value of ambulatory blood pressure : current evidence and clinical implications. Hypertension 35: 844–851. doi: 10.1161/01.HYP.35.3.844
    [98] O'Brien E, Sheridan J, O'Malley K (1988) Dippers and Non-dippers. Lancet 332: 397.
    [99] Kario K, Pickering TG, Umeda Y, et al. (2003) Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: A prospective study. Circulation 107: 1401–1406. doi: 10.1161/01.CIR.0000056521.67546.AA
    [100] Muller JE, Abela GS, Nesto RW, et al. (1994)Triggers, acute risk factors and vulnerable plaques: The lexicon of a new frontier. J Am College Cardiology 23: 809–813.
    [101] Li Y, Thijs L, Hansen TW, et al. (2010) Prognostic value of the morning blood pressure surge in 5645 subjects from 8 populations. Hypertension 55: 1040–1048. doi: 10.1161/HYPERTENSIONAHA.109.137273
    [102] Neutel JM, Schnaper H, Cheung DG, et al. (1990) Antihypertensive effects of β-blockers administered once daily: 24-hour measurements. Am Heart J 120: 166–171. doi: 10.1016/0002-8703(90)90174-V
    [103] Meredith PA, Donnelly R, Elliott HL, et al. (1990) Prediction of the antihypertensive response to enalapril. J Hypertens 8: 1085–1090. doi: 10.1097/00004872-199012000-00003
    [104] Hermida RC, Calvo C, Ayala DE, et al. (2005) Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens 23: 1913–1922. doi: 10.1097/01.hjh.0000182522.21569.c5
    [105] Kikuya M, Ohkubo T, Asayama K, et al. (2005) Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: The Ohasama study. Hypertension 45: 240–245. doi: 10.1161/01.HYP.0000152079.04553.2c
    [106] Ben-Dov IZ, Kark JD, Ben-Ishay D, et al. (2007) Predictors of All-Cause Mortality in Clinical Ambulatory Monitoring. Hypertension 49: 1235–1241. doi: 10.1161/HYPERTENSIONAHA.107.087262
    [107] Boggia J, Li Y, Thijs L, et al.(2007) Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 370: 1219–1229.
    [108] Fagard RH, Celis H, Thijs L, et al. (2008) Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 51: 55–61. doi: 10.1161/HYPERTENSIONAHA.107.100727
    [109] Fan H-Q, Li Y, Thijs L, et al. (2010) Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens 28: 2036–2045. doi: 10.1097/HJH.0b013e32833b49fe
    [110] Hermida RC, Ayala DE, Mojón A, et al. (2011) Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol 58: 1165–1173. doi: 10.1016/j.jacc.2011.04.043
    [111] Hermida RC, Ayala DE, Mojón A, et al. (2010) Influence of circadian time of hypertension treatment on cardiovascular risk:results of the MAPEC study. Chronob 278: 1629–1651.
    [112] Hermida RC, Ayala DE, Mojón A, et al. (2011) Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 34: 1270–1276. doi: 10.2337/dc11-0297
    [113] Hermida RC, Ayala DE, Mojon A, et al. (2011) Bedtime Dosing of Antihypertensive Medications Reduces Cardiovascular Risk in CKD. J Am Soc Nephrol 22: 2313–2321. doi: 10.1681/ASN.2011040361
    [114] Pogue V, Rahman M, Lipkowitz M, et al. (2008) Disparate Estimates of Hypertension Control From Ambulatory and Clinic Blood Pressure Measurements in Hypertensive Kidney Disease. Hypertension 53.
    [115] Hermida RC (2007)Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study. Chronobiol Int 24: 749–775.
    [116] Minutolo R, Gabbai FB, Borrelli S, et al.(2007) Changing the Timing of Antihypertensive Therapy to Reduce Nocturnal Blood Pressure in CKD: An 8-Week Uncontrolled Trial. Am J Kidney Dis 50: 908–917.
    [117] Hermida RC, Ayala DE, Fernández JR, et al. (2008) Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 51: 69–76. doi: 10.1161/HYPERTENSIONAHA.107.096933
    [118] Carter BL, Chrischilles EA, Rosenthal G, et al. (2014) Efficacy and Safety of Nighttime Dosing of Antihypertensives: Review of the Literature and Design of a Pragmatic Clinical Trial. J Clin Hypertens 16: 115–121. doi: 10.1111/jch.12238
    [119] Ohkubo T, Imai Y, Tsuji I, et al. (1997) Prediction of mortality by ambulatory blood pressure monitoring versus screening blood pressure measurements: a pilot study in Ohasama. J Hypertens 15: 357–364. doi: 10.1097/00004872-199715040-00006
    [120] Guidelines JCS (2012) Guidelines for the Clinical Use of 24 Hour Ambulatory Blood Pressure Monitoring (ABPM) (JCS 2010). Circ J 76: 508–519. doi: 10.1253/circj.CJ-88-0020
    [121] Verdecchia P, Angeli F, Mazzotta G, et al. (2012) Day-night dip and early-morning surge in blood pressure in hypertension: Prognostic implications. Hypertension :34–42.
    [122] Glynn LG, Murphy AW, Smith SM, et al. (2010) Interventions used to improve control of blood pressure in patients with hypertension. The Cochrane.
    [123] Santschi V, Chiolero A, Colosimo AL, et al. (2014) Improving Blood Pressure Control Through Pharmacist Interventions: A Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc 3: e000718. doi: 10.1161/JAHA.113.000718
    [124] Floras JS (2007) Ambulatory blood pressure: facilitating individualized assessment of cardiovascular risk. J Hypertens 25: 1565–1568. doi: 10.1097/HJH.0b013e32829baafe
    [125] Home. Available from: https://medicalhomeinfo.aap.org/Pages/default.aspx
    [126] Ahern DK, Stinson LJ, Uebelacker LA, et al. (2012) E-health blood pressure control program. J Med Pract Manag 28: 91–100.
    [127] Anthony CA, Polgreen LA, Chounramany J, et al. (2015) Outpatient blood pressure monitoring using bi-directional text messaging. J Am Soc Hypertens 9: 375–381. doi: 10.1016/j.jash.2015.01.008
    [128] Zullig LL, Dee Melnyk S, Goldstein K, et al. (2013) The role of home blood pressure telemonitoring in managing hypertensive populations. Curr Hypertens Rep 15: 346–355. doi: 10.1007/s11906-013-0351-6
    [129] Margolis KLK, Asche SES, Bergdall AAR, et al. (2013) Effect of Home Blood Pressure Telemonitoring and Pharmacist Management on Blood Pressure Control. Jama 310: 46. doi: 10.1001/jama.2013.6549
    [130] Margolis KLK, Asche SES, Bergdall ARA, et al (2015) A Successful Multifaceted Trial to Improve Hypertension Control in Primary Care: Why Did it Work? J Gen Intern Med 30: 1665–1672. doi: 10.1007/s11606-015-3355-x
    [131] Green B, Cook A, Ralston J, et al. (2008) Effectiveness of Home Blood Pressure Monitoring, Web Communication, and Pharmacist Care on Hypertension Control: The e-BP Randomized Controlled Trial. Jama 299: 2857–2867. doi: 10.1001/jama.299.24.2857
    [132] Fishman PA, Cook AJ, Anderson ML, et al. (2013) Improving BP control through electronic communications: An economic evaluation. Am J Manag Care 19: 709–716.
    [133] Polgreen LA, Han J, Carter BL, et al. (2015) Cost-Effectiveness of a Physician-Pharmacist Collaboration Intervention to Improve Blood Pressure Control. Hypertension 66: 1145–1151.
    [134] Robins LS, Jackson JE, Green BB, et al. (2013) Barriers and facilitators to evidence-based blood pressure control in community practice. J Am Board Fam Med 26: 539–557. doi: 10.3122/jabfm.2013.05.130060
    [135] Magid D J, Olson K L, Billups S J, et al. (2013) A pharmacist-led, American heart association Heart360 web-enabled home blood pressure monitoring program. Circulation 6: 157–163.
    [136] Bosworth H B, Powers B J, Olsen M K, et al. (2011) Home blood pressure management and improved blood pressure control: Results from a randomized controlled trial. Arch Int Med 171: 1173–1180. doi: 10.1001/archinternmed.2011.276
    [137] Omboni S, Sala E (2015) The pharmacist and the management of arterial hypertension: the role of blood pressure monitoring and telemonitoring. Expert Rev Cardiovasc Ther13: 209–221.
    [138] Ernst ME (2013) Ambulatory blood pressure monitoring: recent evidence and clinical pharmacy applications. Pharmacotherapy 33: 69–83. doi: 10.1002/phar.1167
    [139] James K, Dolan E, O'Brien E (2014). Making ambulatory blood pressure monitoring accessible in pharmacies. Blood Press Monit 19: 134–139. doi: 10.1097/MBP.0000000000000034
    [140] Gregoski MJ, Vertegel A, Shaporev A, et al. (2013) Tension Tamer: delivering meditation with objective heart rate acquisition for adherence monitoring using a smart phone platform. J Altern Complement Med 19: 17–19. doi: 10.1089/acm.2011.0772
    [141] Rifkin DE, Abdelmalek JA, Miracle CM, et al. (2013) Linking clinic and home: a randomized, controlled clinical effectiveness trial of real-time, wireless blood pressure monitoring for older patients with kidney disease and hypertension. Blood Press Monit 18: 8–15. doi: 10.1097/MBP.0b013e32835d126c
    [142] Kim KB, Han HR, Huh B, et al. (2014). The effect of a community-based self-help multimodal behavioral intervention in Korean American seniors with high blood pressure. Am J Hypertens 27: 1199–1208. doi: 10.1093/ajh/hpu041
    [143] Sieverdes JC, Treiber F, Jenkins C, et al. (2013). Improving Diabetes Management With Mobile Health Technology. Am J Med Sci 345: 289–295. doi: 10.1097/MAJ.0b013e3182896cee
    [144] O'Reilly DJ, Bowen JM, Sebaldt RJ, et al. (2014) Evaluation of a Chronic Disease Management System for the Treatment and Management of Diabetes in Primary Health Care Practices in Ontario: An Observational Study. Ont Heal Technol Assess Ser14: 1–37.
    [145] Green BB, Anderson ML, Cook AJ, et al. (2014) E-care for heart wellness: A feasibility trial to decrease blood pressure and cardiovascular risk. Am J Prev Med 46: 368–377. doi: 10.1016/j.amepre.2013.11.009
    [146] Gandhi PU, Pinney S (2014) Management of chronic heart failure: biomarkers, monitors, and disease management programs. Ann Glob Heal 80: 46–54. doi: 10.1016/j.aogh.2013.12.005
    [147] Aberger EW, Migliozzi D, Follick MJ, et al. (2014). Enhancing Patient Engagement and Blood Pressure Management for Renal Transplant Recipients via Home Electronic Monitoring and Web-Enabled Collaborative Care. Telemed J e-Health 20: 850–854. doi: 10.1089/tmj.2013.0317
    [148] Neumann CL, Schulz EG (2014) Interventionelles dezentrales Telemonitoring: Mögliche Indikationen und Perspektiven einer neuen Methode in der Telemedizin. Praxis 103: 519–526. doi: 10.1024/1661-8157/a001642
  • This article has been cited by:

    1. Faran Nabeel, Tahir Rasheed, Rhodol-conjugated polymersome sensor for visual and highly-sensitive detection of hydrazine in aqueous media, 2020, 388, 03043894, 121757, 10.1016/j.jhazmat.2019.121757
    2. Lizeth Parra-Arroyo, Roberto Parra-Saldivar, Ricardo A. Ramirez-Mendoza, Tajalli Keshavarz, Hafiz M. N. Iqbal, 2020, Chapter 7, 978-3-030-47905-3, 173, 10.1007/978-3-030-47906-0_7
    3. Emine Gul Cansu Ergun, Three in one sensor: a fluorometric, colorimetric and paper based probe for the selective detection of mercury(ii), 2021, 45, 1144-0546, 4202, 10.1039/D1NJ00085C
    4. Tahir Rasheed, Faran Nabeel, Muhammad Adeel, Komal Rizwan, Muhammad Bilal, Hafiz M.N. Iqbal, Carbon nanotubes-based cues: A pathway to future sensing and detection of hazardous pollutants, 2019, 292, 01677322, 111425, 10.1016/j.molliq.2019.111425
    5. Tahir Rasheed, Muhammad Adeel, Faran Nabeel, Muhammad Bilal, Hafiz M.N. Iqbal, TiO2/SiO2 decorated carbon nanostructured materials as a multifunctional platform for emerging pollutants removal, 2019, 688, 00489697, 299, 10.1016/j.scitotenv.2019.06.200
    6. Sagar K. Patil, Dipanwita Das, A novel rhodamine-based optical probe for mercury(II) ion in aqueous medium: A nanomolar detection, wide pH range and real water sample application, 2020, 225, 13861425, 117504, 10.1016/j.saa.2019.117504
    7. S.М. Rogacheva, A.B. Shipovskaya, I.А. Ivanova, N.O. Gegel, Film polysaccharide matrices for immobilization of hydrophilic fluorescence probes, 2020, 1, 26663511, 100022, 10.1016/j.sintl.2020.100022
    8. Nisar Ali, Hira Zaman, Muhammad Bilal, Anwar-ul-Haq Ali Shah, Muhammad Shahzad Nazir, Hafiz M.N. Iqbal, Environmental perspectives of interfacially active and magnetically recoverable composite materials – A review, 2019, 670, 00489697, 523, 10.1016/j.scitotenv.2019.03.209
    9. Tahir Rasheed, Faran Nabeel, Luminescent metal-organic frameworks as potential sensory materials for various environmental toxic agents, 2019, 401, 00108545, 213065, 10.1016/j.ccr.2019.213065
    10. Nisar Ali, Adnan Khan, Muhammad Bilal, Sumeet Malik, Syed Badshah, Hafiz M. N. Iqbal, Chitosan-Based Bio-Composite Modified with Thiocarbamate Moiety for Decontamination of Cations from the Aqueous Media, 2020, 25, 1420-3049, 226, 10.3390/molecules25010226
    11. Tahir Rasheed, Muhamad Bilal, Adeel Ahmad Hassan, Faran Nabeel, Ram Naresh Bharagava, Luiz Fernando Romanholo Ferreira, Hai Nguyen Tran, Hafiz.M.N. Iqbal, Environmental threatening concern and efficient removal of pharmaceutically active compounds using metal-organic frameworks as adsorbents, 2020, 185, 00139351, 109436, 10.1016/j.envres.2020.109436
    12. Tahir Rasheed, Faran Nabeel, Komal Rizwan, Muhammad Bilal, Tariq Hussain, Sabir Ali Shehzad, Conjugated supramolecular architectures as state-of-the-art materials in detection and remedial measures of nitro based compounds: A review, 2020, 129, 01659936, 115958, 10.1016/j.trac.2020.115958
    13. Angel M. Villalba-Rodríguez, Lizeth Parra-Arroyo, Reyna Berenice González-González, Roberto Parra-Saldívar, Muhammad Bilal, Hafiz M.N. Iqbal, Laccase-assisted biosensing constructs – Robust modalities to detect and remove environmental contaminants, 2022, 5, 26660164, 100180, 10.1016/j.cscee.2022.100180
    14. Tahir Rasheed, Sameera Shafi, Muhammad Bilal, Tariq Hussain, Farooq Sher, Komal Rizwan, Surfactants-based remediation as an effective approach for removal of environmental pollutants—A review, 2020, 318, 01677322, 113960, 10.1016/j.molliq.2020.113960
    15. Himali Upadhyay, Uma Harikrishnan, Devanshi Bhatt, Namrata Dhadnekar, Kapil Kumar, Manthan Panchal, Calixarene: The Dawn of a New Era in Forensic Chemistry, 2022, 26, 13852728, 2005, 10.2174/1385272827666230118094847
    16. Raguraman Lalitha, Sivan Velmathi, A Study of Small Molecule-Based Rhodamine-Derived Chemosensors and their Implications in Environmental and Biological Systems from 2012 to 2021: Latest Advancement and Future Prospects, 2024, 34, 1053-0509, 15, 10.1007/s10895-023-03231-1
    17. Tahir Rasheed, 2024, 9780443132551, 193, 10.1016/B978-0-443-13255-1.00009-9
    18. Yi Cai, Wei Li, Ming Li, Cheng Yao, Yong Zhao, The “All-in-One” Colorimetric System for In Situ Synthesis of Gold Nanoparticles and Mercury Detection Assisted by Nonthermal Microplasma, 2024, 73, 0018-9456, 1, 10.1109/TIM.2024.3385841
    19. Mani Rajasekar, Pavithra Baskaran, Jennita Mary, Sivakumar Meenambigai, Masilamani Selvam, Review of current developments in rhodamine derivatives-based photoresponsive chemosensors for ion detection, 2024, 162, 13877003, 112143, 10.1016/j.inoche.2024.112143
  • Reader Comments
  • © 2017 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(6990) PDF downloads(1072) Cited by(2)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog